Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma

Inclusion Criteria: * Diagnosis of CD30-positive HL by immunohistochemistry or flow cytometry * Must have failed or relapsed following second line chemotherapy or radiation or failed/relapsed following autologous stem cell transplant * Bi-measurable disease * ECOG Performance Status of 0 - 2 * Meet all screening laboratory values Exclusion Criteria: * Previous treatment with any other anti-CD30 antibody * History of allogeneic transplant * Any tumor lesion greater than or equal to 10 cm in diameter * Any active or chronic significant infection * Underlying medical condition which will make the administration of MDX- 1401 hazardous * Concomitant corticosteroids, chemotherapy, investigational agents, other anti-HL biologics, or radiation therapy